Cytotoxic activity of pegylated nanoliposomal hydroxyurea in MCF-7 cell line

Aim and Annual, Breast cancer takes the lives of thousands of people. Nowadays, nanotechnology is the major topics of scientific societies in targeted pharmacy field. The nanotechnology helps to control time, position and velocity of drug release. Hydroxyurea used as medicine in Breast cancer treatment that the use it has side effects. Because of this, In order to reduction side effects, increase efficiency and comfort of patients used the nano drug delivery. Certain ratios of Phosphatidylcholine, cholesterol and polyethylene glycol 2000 were synthesized and then the hydroxyurea drug was added. The mean diameter of pegylated nanoliposomal hydroxyurea was measured with the Zeta sizer device. Encapsulation efficiency and the pattern of drug release from pegylated nanoliposomes have been studied using spectrophotometery and dialysis methods. The cytotoxicity effect of the nanoliposomal drug was measured by the MTT assay. Results The mean diameter of pegylated nanoliposomal hydroxyurea was estimated 338.2 nanometers. Its encapsulation efficiency was 64.212±0.173 percents. The pattern of drug release from pegylated nanoliposomal drug within 28 hours was 25.85 %. of this investigation also showed that the cytotoxic properties of pegylated nanoliposomal hydroxyurea was 38.93% more than standard hydroxyurea. Polyethylene glycol demonstrated the increasing solubility of drug and in turn its better contact with the target cells.